Attached files
| file | filename |
|---|---|
| S-1/A - S-1/A - Phio Pharmaceuticals Corp. | d271779ds1a.htm |
| EX-4.3 - EX-4.3 - Phio Pharmaceuticals Corp. | d271779dex43.htm |
| EX-5.1 - EX-5.1 - Phio Pharmaceuticals Corp. | d271779dex51.htm |
| EX-1.1 - EX-1.1 - Phio Pharmaceuticals Corp. | d271779dex11.htm |
| EX-3.11 - EX-3.11 - Phio Pharmaceuticals Corp. | d271779dex311.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
RXi Pharmaceuticals Corporation
Marlborough, Massachusetts
We hereby consent to the use in the Prospectus constituting a part of this Registration Statement of our report dated March 30, 2016 (except for the stock split discussed in Note 13, as to which date is April 18, 2016), relating to the financial statements of RXi Pharmaceuticals Corporation, which is contained in that Prospectus.
We also consent to the reference to us under the caption “Experts” in the Prospectus.
| /s/ BDO USA, LLP |
| Boston, MA |
| November 29, 2016 |